Status:

UNKNOWN

Assessment on Effects of Tongjiang Granule in Treating Nonerosive Reflux Disease Overlapping Epigastric Pain Syndrome

Lead Sponsor:

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Collaborating Sponsors:

First Affiliated Hospital of Heilongjiang Chinese Medicine University

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine

Conditions:

Gastroesophageal Reflux

Functional Dysphonia

Eligibility:

All Genders

18-70 years

Phase:

PHASE1

PHASE2

Brief Summary

Overlapping gastrointestinal symptoms of functional gastrointestinal diseases (FGIDs) is an internationally recognized problem in modern medical diagnosis and treatment. Such patients show more physic...

Detailed Description

Overlapping gastrointestinal symptoms of functional gastrointestinal diseases (FGIDs) is an internationally recognized modern medical treatment problem. More than 40.7% of people worldwide suffer from...

Eligibility Criteria

Inclusion

  • It meets the diagnostic criteria of nonerosive reflex disease(NERD)and epigastric pain syndrome(EPS)
  • It meets the diagnostic criteria of liver-stomach depression-heat syndrome of traditional Chinese medicine
  • Age between 18 and 70 years old
  • Patients have informed consent and are willing to receive corresponding treatment

Exclusion

  • Patients with active peptic ulcer, gastrointestinal hemorrhage, severe dysplasia of gastric mucosa or suspected malignant change, achalasia or postoperative achalasia
  • There are other organic diseases of the digestive system (such as acute and chronic pancreatitis, cirrhosis, etc.), or systemic diseases that affect the gastrointestinal motility, such as hyperthyroidism, diabetes mellitus over 10 years, chronic renal insufficiency, spirit (the score of SAS and SDS shows severe anxiety or depression), nervous system diseases, etc
  • Patients with severe organ diseases such as heart, liver and kidney (such as ALT, AST more than 2 times of normal value), hematopoietic system diseases and tumors
  • HP infection was positive (bacterial culture, histological examination, urea breath test, rapid urease test and fecal antigen test were positive);
  • People with a history of gastric / abdominal surgery (excluding appendectomy);
  • Pregnant and lactating women;
  • People with a history of allergies to all the test drugs
  • Subjects who are participating in other clinical trials or have participated in other clinical trials within 4 weeks
  • Other situations that reduce the possibility of enrollment or complicate enrollment according to the judgment of the researcher, such as frequent changes in working environment and other situations that are easy to cause loss of follow-up.

Key Trial Info

Start Date :

March 26 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 1 2024

Estimated Enrollment :

228 Patients enrolled

Trial Details

Trial ID

NCT05312463

Start Date

March 26 2022

End Date

October 1 2024

Last Update

April 5 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Beijing, Beijing Municipality, China, 100091